CombinatoRx discovers novel, patentable drug products through a proprietary, high throughput screen of combinations of approved drugs. This unique approach has enabled the company to move from screening leads to clinical trials in less than a year, and to put six novel therapies into Phase I/II trials. CEO Alexis Borisy was named Innovator of the Year by MIT’s Technology Review 2003. Flagship General Partner Doug Cole works closely with the company.

www.combinatorx.com